← Back to patent-cliff list
Imdatifan
Tier C — Watch / tradeImdatifan
NiKang Therapeutics Inc
Originator
-
First approval
-
Expiry (public)
No sales data
Peak sales
Small molecule
Type
Targets：EPAS1
Indications (approved)：Renal cell carcinoma, Solid tumour, von Hippel-Lindau syndrome, Genitourinary neoplasm, Urinary tract disease, Urinary tract neoplasm, 缺氧, Kidney disease
Regional status
US
Discontinued
2021-10-26
EU
-
China
Phase II
2025-07-08
Japan
-
Synthetic routes & intermediates
Routes not yet onboarded — the daily pipeline enriches by priority (approved small molecules first); this page updates automatically.
Frequently asked questions
What are the approved indications of Imdatifan?
Approved indications include: Renal cell carcinoma, Solid tumour, von Hippel-Lindau syndrome, Genitourinary neoplasm, Urinary tract disease, Urinary tract neoplasm, 缺氧, Kidney disease.
When does the Imdatifan patent expire?
No public expiry year is available for Imdatifan yet; this page updates once verified.
How do I get a quote for Imdatifan intermediates?
Open the CAS profile of the target intermediate from this page, or submit an RFQ directly — the CAS enters the matching flow automatically and the supply network responds with quotes.
Source: cross-verified data (structured fields only) · 2026-10-06